Introduction
============

With the current increasing use of a combination of antiretroviral (ART) drugs, HIV-1/AIDS has become a treatable, chronic disease and patients can now expect improved overall health and life span ([@B11]). ART drugs include three main classes of protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors (NRTIs), and/or non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, ART treatment of HIV-1-infected patients has been associated with an increased risk of metabolic consequences, lipodystrophy syndrome, and neuropsychiatric complications ([@B21]; [@B35]; [@B14]; [@B36]). ART treatment cause metabolic consequences such as abnormal glucose metabolism, insulin resistance, dyslipidemia, fatty liver, therefore resulting in type 2 diabetes, cardiovascular diseases, and stroke ([@B35]).

The cumulative use, adherence, and treatment regimen of ART drugs used may affect the risk of development of hyperlipidemia in HIV-1-infected patients ([@B23]; [@B1]; [@B46]). Signaling of the AMP-activated protein kinase (AMPK) protein and its downstream target, acetyl-coenzyme A carboxylase protein, are involved in lipid metabolism, and may contribute to hepatic tissue lipids and hyperlipidemia ([@B50], [@B49]; [@B20]). In addition, adipogenic differentiation markers and transcription factors including fatty acid binding protein 4 (FABP4), adiponectin (Adipoq), peroxisome proliferator-activated receptor-gamma (PPARg), lipoprotein lipase (Lpl), sterol regulatory element-binding protein-1 (SREBP-1), CCAAT enhancer-binding proteins (CEBPs), and fatty acid synthetase (FAS) in adipose tissues may contribute to adipogenesis ([@B24]; [@B41]; [@B16]; [@B9]). Several drugs including thiazolidinediones and leptins have ameliorated symptoms in patients on ART ([@B33]; [@B12]; [@B47]). Thiazolidinediones are a class of PPAR agonists, that upregulate PPAR-dependent genes such as adiponectin, and showed a beneficial effect on limb fat mass in HIV-1/ART-associated lipodystrophy syndrome patients ([@B12]). Furthermore, leptin expression has been shown to be regulated by several transcriptional factors including CEBPb ([@B27]). Leptin therapy has been found to improve hyperlipidemia and lipodystrophy in HIV-1-lipodystrophic patients ([@B33]; [@B47]). Furthermore, leptin may have important physiological effects on brain function ([@B18]; [@B8]). Leptins are known to have a significant effect on the hippocampus, a key brain region for cognition, and therefore may play important roles in neurologic complications ([@B29],[@B30]). However, further investigation is needed into the effects of these ART drugs and their action mechanisms.

Due to the complicated ART drug combinations involved in ART treatment and the lack of an appropriate animal experimental model, determining which PIs, NRTIs, and NNRTIs may be the main cause of ART-associated lipodystrophic syndrome, metabolic consequences, and neuropsychiatric complications is a complex task. Our study demonstrates that Taiwanese HIV-1-infected patients who received an NRTI/NRTI-containing regimen had the highest hyperlipidemia risk, followed by patients receiving a PI-containing regimen ([@B46]). Amongst these NRTI/NRTI-containing regimens, the abacavir/lamivudine (Aba/Lam) and lamivudine/zidovudine (Lam/Zido) regimens were associated with the highest risk of hyperlipidemia. Amongst the PI-containing regimens, the lopinavir/ritonavir (Lop/Rit) regimen was associated with the highest risk of hyperlipidemia.

As previous work from our group demonstrated that a high risk of hyperlipidemia was observed in HIV-1-infected patients who received ART regimens in Taiwan, further studies are needed to investigate the most commonly used ART regimens to better understand their effect and possible mechanisms. Therefore, this study was designed to determine the effect of ART drugs on the development of metabolic consequences, lipodystrophy syndrome, cognitive and motor abilities in C57BL/6 mice. Mice were administered Aba/Lam, Lam/Zido, or Lop/Rit, orally, once daily for a period of 4 weeks. Here, we show that Aba/Lam and Lop/Rit regimens may contribute to the development of neurological and metabolic impairments in mice, suggesting that they are also likely to contribute to metabolic consequences, lipodystrophy syndrome, and neurologic complications in humans.

Materials and Methods {#s1}
=====================

Animals
-------

Six- to eight-week-old male C57Bl/6 mice were purchased from the National Laboratory Animal Center in Taiwan (AAALAC approved institute for animal propagation). All mice were housed in standard caging in temperature and humidity-controlled rooms with 12:12-h light:dark cycle and ad libitum access to dry laboratory food and water. Cages were cleaned once weekly. The use of mice our experiments complied with the 3R guidelines (3R: Replace, reduce, and refine) for the use of experimental animals. This study was reviewed and approved for all experimental protocols by the Institutional Animal Care and Use Committee (IACUC) in China Medical University, Taichung, Taiwan.

Study Design
------------

C57Bl/6 mice (6- to 8-week-old) were administered either 150/75 mg/kg Aba/Lam (Kivexa, Abbott Laboratories), 150/75 mg/kg Lam/Zido (Combivir, ViiV Healthcare, GlaxoSmithKline plc), or 150/37.5 mg/kg Lop/Rit (Kaletra, Abbott Laboratories), daily, via the oral route. The drugs were diluted in a control solution of 10% ethanol/15% propylene glycol. The control group of mice received only a solution of 10% ethanol/15% propylene via oral gavage with 100 μl. The dosage conversion was based on body surface area (BSA) normalization factors, which translate from 10 mg/kg in humans to approximately 125 mg/kg in mice ([@B39]). Following a period of 4 weeks for daily treatment, groups of mice were sacrificed by CO~2~ asphyxiation (*n* = 4 per treatment group per time; repeated twice).

Body weight was measured daily for a period of 4 weeks (**Figure [1](#F1){ref-type="fig"}**). Passive avoidance tests (cognitive performance) were performed at day 29 (the Gemini Avoidance System, San Diego Instruments, San Diego, CA, United States; **Figure [2](#F2){ref-type="fig"}**). Briefly, mice were placed in the right chamber (bright room). After 5 s, the light in the right chamber was turned on, and the gate was opened simultaneously. Once the mice entered the left chamber (dark room), the gate was then quickly closed, and the entry latency (sec) was recorded. Each trial was repeated three times. In addition, a timed rotarod test (motor performance) was also performed at day 30 (Rotamex, Columbus Instrument, OH, United States; **Figure [2](#F2){ref-type="fig"}**). Briefly, mice were placed on a Rotamex with an initial speed of 4 rpm. The speed of the Rotamex was increased by 0.5 rpm per 5 s until the maximum 20 rpm/min speed was reached. Each mouse was tested on six separate occasions.

![Effects of antiretroviral drugs on body weight in mice. Male C57BL/6 mice were orally administrated daily with control (open circles), Aba/Lam (abacavir/lamivudine (NRTI/NRTI); open squares), Lam/Zido (lamivudine/zidovudine (NRTI/NRTI); closed triangles), and Lop/Rit (Lopinavir/ritonavir (PI); open diamond). These four groups were evaluated daily for a period of 4 weeks for their body weight (gram). All data are mean ± SEM for each group (8--10 mice per group). Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice at the same time point.](fphar-09-01004-g001){#F1}

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on cognitive and motor abilities in the C57Bl/6 mice. **(A)** Effects of antiretroviral drugs on cognitive performance in the passive avoidance test. **(B)** Effects of antiretroviral drugs on motor performance in the rotarod test. All data are mean ± SEM for each group (8--10 mice per group). Data are expressed as the time (sec) and analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice.](fphar-09-01004-g002){#F2}

Blood was collected by cardiac puncture of terminally anesthetized mice at day 31. Clotted blood was then centrifuged at 3,000 × *g* for 30 min in order to obtain serum. The serum levels of leptin (**Figure [3](#F3){ref-type="fig"}**; EML2001-1; Mouse Leptin ELISA Kit) and adiponectin (**Figure [3](#F3){ref-type="fig"}**; EMA2500-1; Mouse Adiponectin ELISA Kit) were also evaluated by ELISA according to the manufacturer's protocol (Assaypro, MO, United States). The serum levels of total cholesterol, HDL-cholesterol, and triglycerides were measured colorimetrically using commercially available kits (**Figure [4](#F4){ref-type="fig"}**; SPOTCHEM EZ SP-4430, ARKRAY, Yu-Shing Biotech., Ltd, Taipei, Taiwan).

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on serum levels of adipokines in the C57Bl/6 mice. **(A)** Effects of antiretroviral drugs on serum levels of leptin. **(B)** Effects of antiretroviral drugs on serum levels of adiponectin. All data are mean ± SEM for each group (8--10 mice per group). Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice.](fphar-09-01004-g003){#F3}

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on serum lipid levels in the C57Bl/6 mice. **(A)** Effects of antiretroviral drugs on serum level of total cholesterol. **(B)** Effects of antiretroviral drugs on serum level of triglyceride. **(C)** Effects of antiretroviral drugs on serum level of HDL-c. All data are mean ± SEM for each group (8--10 mice per group). Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice at the same time point.](fphar-09-01004-g004){#F4}

Liver tissue samples were collected from euthanized mice for Western blot analysis (**Figure [5](#F5){ref-type="fig"}**). Briefly, liver tissue samples were homogenized on ice with the RIPA protein extraction kit (Pierce, Thermo Fisher Scientific, Rockford, IL, United States) with a PI (complete EDTA-freePI, Roche Life Science, Sigma-Aldrich) according to the manufacturer's protocol. The cell lysates were centrifuged to remove insoluble protein. The protein concentrations of the supernatants of cell lysates were determined using the BCA protein assay kit. Samples of cell lysates with equal protein concentrations were subjected to 12% SDS-PAGE and then transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, United States). The membranes were then incubated with primary antibodies overnight at 4°C. The primary antibodies included anti-phospho-AMPKa (Thr172; 40H9, catalog number 2535), anti-AMPKa (D5A2, catalog number 5831), anti-phospho-Acetyl-CoA Carboxylase (Ser79; D7D11, catalog number 11818), and anti-Acetyl-CoA Carboxylase (C83B10, catalog number 3676) from Cell Signaling Technology, Inc. (Beverly, MA, United States), anti-actin (mAbGEa, catalog number NB100-74340) from Novus Biologicals, and anti-GAPDH (catalog number 60004-1-Ig) antibodies from Proteintech Group Inc. (Rosemont, IL, United States). The membranes were then incubated with alkaline phosphatase-conjugated secondary antibodies (Sigma-Aldrich). Signals were visualized using a chemiluminescence kit (Chemicon), following the manufacturer's protocol. The Western blot band intensities were quantified by using Image J software. Phospho-AMPKa, total AMPKa, Phospho-ACC, total ACC, and GAPDH were all quantified from their appropriate protein mass bands on the blot. Relative ratios of band intensity of p-AMPKa/AMPKa and ACC/GAPDH were compared with the controls. All data are mean ± SEM for each group (8--10 mice per group). Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice at the same time point.

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on total cholesterol content, and lipid metabolism-related AMPK and ACC proteins in the liver tissue of C57Bl/6 mice. **(A)** Total cholesterol levels of each group were detected in the liver tissue in mice and expressed in bar chart. **(B)** Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on phosphorylation and expression of both AMPKa and ACC proteins by using Western blot analysis. **(C)** Relative ratios of band intensity of p-AMPKa/AMPKa and ACC/GAPDH when compared with the controls. Western blot band intensities were quantified by using Image J software. All data are mean ± SEM for each group (8--10 mice per group). Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated mice as compared with the control mice at the same time point.](fphar-09-01004-g005){#F5}

For HepG2 (human hepatocellular carcinoma) cell culture, the cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 U/mL streptomycin, and 2 mM [L]{.smallcaps}-glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, United States). Human HepG2 cells were treated with ART drugs for 24 h at the concentrations indicated (**Figure [6](#F6){ref-type="fig"}**). The cells were then lysed in RIPA buffer and the proteins resolved by SDS-PAGE and western blot analysis as previously described for mouse liver tissue samples (**Figure [5](#F5){ref-type="fig"}**). Western blot band intensities were quantified using ImageJ, as described above. Oleic acid-treated HepG2 cells are used as the lipid accumulation controls and the controls to inhibit the AMPK and ACC signaling pathway.

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on total cholesterol content, and lipid metabolism-related AMPK and ACC proteins in human HepG2 hepatocytes. **(A)** Total cholesterol levels of each group were assayed and expressed in bar charts. **(B)** Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on phosphorylation and expression of both AMPKa and ACC proteins by using Western blot analysis. **(C)** Relative ratios of band intensity of p-AMPKa/AMPKa and p-ACC/ACC when compared with the controls. All data are mean ± SEM for each group. Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated HepG2 cells as compared with the control cells. Oleic acid-treated HepG2 cells are used as the lipid accumulation controls and the controls to inhibit the AMPK and ACC signaling pathway.](fphar-09-01004-g006){#F6}

For 3T3-L1 (mouse preadipocyte) cell culture, the cells were maintained in Dulbecco's modified Eagle's medium as previously described. Mouse 3T3-L1 preadipocytes were differentiated in differentiation medium in the presence of ART drugs for 7 days at the concentrations indicated (**Figure [7](#F7){ref-type="fig"}**). Oil Red O quantification analysis of ART drugs in 3T3-L1 preadipocytes differentiation under adipocyte differentiation medium (Cat No.: DIF001, 3T3-L1 Differentiation Kit, Sigma-Aldrich, Inc.) was performed by using Lipid (Oil Red O) Staining Kit (Cat No.: K580-24, BioVision).

![Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on mouse 3T3-L1 preadipocytes differentiation. Mouse 3T3-L1 preadipocytes were differentiated in differentiation medium in the presence of the indicated concentrations of antiretroviral drugs for 7 days. **(A)** Oil Red O quantification analysis of antiretroviral drugs in 3T3-L1 preadipocytes differentiation under adipocyte differentiation medium. Effect of antiretroviral drugs on the relative mRNA expression levels for **(B)** CEBPb **(C)** FABP4, **(D)** adipoq, **(E)** PPARg, **(F)** Lpl, **(G)** SREBP-1, and **(H)** FAS when compared with the controls by using RT-qPCR analysis. All data are mean ± SEM for each group for three independent experiments. Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated cells as compared with the controls.](fphar-09-01004-g007){#F7}

Cellular RNA was isolated from cells treated with ART drugs using a QIAamp^®^ RNA Mini Kit according to the manufacturer's instructions (Qiagen, Valencia, CA, United States). RNAs were eluted in 60 μL buffer. For Roche probe and primer hybridization assays (Universal ProbeLibrary System Assay Design, Roche), the primers used for quantitative PCR (qPCR) amplification were found by using ProbeFinder (a web-based software tool) as follows: *CEBP-b*, forward: 5'-tgatgcaatccggatcaa-3' and reverse: 5'-cacgtgtgttgcgtcagtc-3' (UPL probe number 102). Reverse transcription and Real-time RT-PCR was performed as previously described ([@B25]). The genomic DNAs were removed by RNase-Free DNase Set (Cat No.: 79254, Qiagen) and the primers designed for qPCR were all spanned across an exon-exon junction as described by Roche probe and primer hybridization assays.

Statistical Analyses
--------------------

All data were calculated as mean ± SEM for each group for three independent experiments using GraphPrism software (GraphPad Software, Inc., La Jolla, CA, United States). All data were analyzed using two-tailed, unpaired student *t*-tests to determine statistical differences in mice, HepG2 cells, and 3T3-L1 cells. All *p*-values of less than 0.05 were considered to be statistically significant.

Results
=======

Effects of ART Drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on Body Weight in C57Bl/6 Mice
------------------------------------------------------------------------------------

Patients who received nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)-containing regimens were found to have the highest hyperlipidemia risk, followed by those receiving PI- containing and non-NRTI-containing regimens ([@B46]). The current study was undertaken to determine the effects of ART drug regimens Aba/Lam, Lam/Zido, and Lop/Rit, on both metabolic and cognitive function in C57Bl/6 mice. Six- to eight-week-old male C57Bl/6 mice were administered with either control (the mixture of 10% ethanol/15% propylene) or Aba/Lam (150/75 mg/kg) (Kivexa, Abbott Laboratories), or Lam/Zido (150/75 mg/kg) (Combivir, ViiV Healthcare, GlaxoSmithKline plc), or Lop/Rit (150/37.5 mg/kg) (Kaletra, Abbott Laboratories), daily via the oral route for a period of 4 weeks. The body weight of the mice was recorded regularly as a health index. As shown in **Figure [1](#F1){ref-type="fig"}**, the treated mice showed no significant differences from the control mice. These data suggest that the drugs had no significant effect on body weight.

Effects of ART Drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on Cognitive and Motor Abilities in C57Bl/6 Mice
------------------------------------------------------------------------------------------------------

To investigate the effects of ART drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on cognitive and motor abilities, passive avoidance and rotarod tests were used for behavioral analyses. The passive avoidance test was used for cognitive function evaluation following 4 weeks of ART drug exposure in this study. The passive avoidance test is a fear-aggravated test that is used to evaluate learning and memory in rodents with central nervous system (CNS) disorders^[1](#fn01){ref-type="fn"}^ and is also useful for evaluating the effect of exposure to chemicals on learning and memory as well as for studying the mechanisms involved in cognition ([@B2]). By recording the entry latency (sec), we observed that Aba/Lam and Lop/Rit treatments resulted in cognitive impairment (**Figure [2A](#F2){ref-type="fig"}**; *p* = 0.044 for the Aba/Lam treated group; *p* = 0.034 for the Lop/Rit treated group). In addition, the rotarod test is a very commonly used test for evaluating motor performance in mice. The time remaining on rotarod was measured when the mice were on an accelerating rotating cylinder. As shown in **Figure [2B](#F2){ref-type="fig"}**, there were significant differences between these groups. By recording the time on rotarod when accelerating the rotating cylinder, we observed that treatment of mice with Aba/Lam, Lam/Zido, or Lop/Rit did lead to motor impairment (**Figure [2B](#F2){ref-type="fig"}**; *p* \< 0.0001 for the Aba/Lam treated group; *p* = 0.0436 for the Lam/Zido treated group; *p* = 0.0059 for the Lop/Rit treated group).

Effects of ART Drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on Metabolic Parameters in C57Bl/6 Mice
---------------------------------------------------------------------------------------------

Following a period of 4 weeks for daily treatment regimen of either control or abacavir/lamivudine, or lamivudine/zidovudine, or lopinavir/ritonavir administered orally, the blood samples were collected to obtain their serum. The serum levels of leptin, adiponectin, total cholesterol, HDL-cholesterol, and triglycerides from these groups were measured (**Figures [3](#F3){ref-type="fig"}**, **[4](#F4){ref-type="fig"}**). As shown in **Figure [3A](#F3){ref-type="fig"}**, there were significant differences in serum levels of leptin. Lower serum levels of leptin were observed in mice treated with Aba/Lam than in the controls (*p* = 0.012 for the Aba/Lam treated group). However, there was no significant difference in the serum level of adiponectin between these groups (**Figure [3B](#F3){ref-type="fig"}**).

Serum samples were obtained following treatment with ART drugs as described. As shown in **Figure [4A](#F4){ref-type="fig"}**, increased serum levels of total cholesterol were observed in mice treated with Lop/Rit (*p* = 0.0003 for the Lop/Rit treated group). There were no significant differences in the serum levels of triglyceride (**Figure [4B](#F4){ref-type="fig"}**). Furthermore, increased serum levels of HDL-c were observed in mice treated with Lop/Rit (**Figure [4C](#F4){ref-type="fig"}**; *p* = 0.0449 for the Lop/Rit treated group). These results suggest that mice treated with Lop/Rit, may show increased serum levels of total cholesterol and HDL-c, respectively.

Studies have reported that the signaling mechanism involved in the phosphorylation and expression of AMPK protein and its downstream target, ACC protein, results in fatty acid oxidation and lipid synthesis, two important lipid metabolism-related proteins of hepatic tissue lipids and hyperlipidemia ([@B50], [@B49]; [@B20]). Phosphorylation and expression of both AMPKa and ACC proteins in mice were also detected using western blot analysis.

As shown in **Figure [5A](#F5){ref-type="fig"}**, the Aba/Lam and Lop/Rit regimens were found to significantly increase intracellular lipid accumulation in comparison to that observed in the controls in the total cholesterol quantification assay (*p* = 0.0401 for the Aba/Lam treated group; *p* = 0.0102 for the Lop/Rit treated group). As shown in **Figures [5B,C](#F5){ref-type="fig"}**, the phosphorylation of AMPKa protein decreased in groups treated with Aba/Lam and Lam/Zido when compared with the control level (*p* = 0.0183 for the Aba/Lam treated group; *p* = 0.0007 for the Lam/Zido treated group). The protein expression of ACC significantly decreased in the groups treated with Aba/Lam and Lop/Rit in comparison with the control level (*p* = 0.0065 for the Aba/Lam treated group; *p* = 0.0019 for the Lop/Rit treated group).

Effects of ART Drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on the Lipid Accumulation, Phosphorylation and Expression of Both AMPKa and ACC Proteins in Human HepG2 Hepatocytes
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether ART drugs affect lipogenesis, hepG2 hepatocytes were treated with Aba/Lam, Lam/Zido, or Lop/Rit. Oleic acid-treated HepG2 cells are used as the lipid accumulation controls and the controls to inhibit the AMPK and ACC signaling pathway. Total cholesterol levels of each group were assayed and expressed in bar charts (**Figure [6A](#F6){ref-type="fig"}**). As shown, treatment with oleic acid, Aba/Lam, Lam/Zido, and Lop/Rit led to intracellular total cholesterol accumulation (*p* = 0.0047 for the oleic acid treated group; *p* = 0.0074 for the Aba/Lam treated group; *p* = 0.0034 for the Lam/Zido treated group; *p* = 0.0260 for the Lop/Rit treated group). The phosphorylation and expression of the AMPKa and ACC proteins were subsequently determined using western blot analysis. As shown in **Figures [6A,B](#F6){ref-type="fig"}**, treatment with oleic acid, Aba/Lam, Lam/Zido, and Lop/Rit led to decreased phosphorylation of the AMPK protein (*p* = 0.0052 for the oleic acid treated group; *p* = 0.0109 for the Aba/Lam treated group; *p* = 0.0012 for the Lam/Zido treated group; *p* = 0.0007 for the Lop/Rit treated group). Similarly, treatment with oleic acid, Aba/Lam, Lam/Zido, and Lop/Rit led to decreased phosphorylation of the ACC protein (*p* = 0.0243 for the oleic acid treated group; *p* = 0.0027 for the Aba/Lam treated group; *p* = 0.0299 for the Lam/Zido treated group; *p* = 0.0162 for the Lop/Rit treated group).

Effects of ART Drugs (Aba/Lam, Lam/Zido, and Lop/Rit) on Lipid Accumulation and Adipocyte Differentiation Marker in 3T3-L1 Pre-adipocytes
-----------------------------------------------------------------------------------------------------------------------------------------

Long term ART use has been associated with lipodystrophic syndrome, which causes alterations in body fat distribution and lipid metabolism ([@B31]; [@B43]). To evaluate the effects of Aba/Lam, Lam/Zido, and Lop/Rit on pre-adipocyte differentiation, 3T3-L1 preadipocytes were cultured for 7 days in the presence of ART drugs at the concentrations indicated (**Figure [7](#F7){ref-type="fig"}**). As shown in **Figure [7A](#F7){ref-type="fig"}**, the Aba/Lam and Lop/Rit regimens were found to significantly decrease intracellular lipid accumulation in comparison to that observed in the controls in the Oil red O quantification assay (*p* = 0.0189 for the Aba/Lam treated group; *p* = 0.0021 for the Lop/Rit treated group). However, no significant differences in lipid accumulation were observed between Lam/Zido-treated cells and the controls. These results suggest that exposure to either Aba/Lam or Lop/Rit during pre-adipocyte differentiation significantly reduces lipid accumulation.

Aba/Lam and Lop/Rit significantly reduced lipid accumulation in differentiating adipocytes. Several adipogenic differentiation markers and transcription factors are involved in the molecular mechanism of adipogenesis ([@B24]; [@B41]; [@B16]; [@B9]). In this study, we examined the expression of adipogenic differentiation markers and transcription factors by incubating 3T3-L1 pre-adipocytes with either Aba/Lam or Lop/Rit for 7 days using RT-qPCR analysis (**Figure [7](#F7){ref-type="fig"}**). These adipogenic differentiation markers and transcription factors include FABP4, adipoq, PPARg, Lpl, SREBP-1, CEBPb, and FAS proteins. As shown, there were no significant differences in these adipogenic differentiation markers and transcription factors, except for the CEBPb protein. 3T3-L1 pre-adipocytes treated with Aba/Lam or Lop/Rit, showed the most significant inhibition of CEBPb expression (**Figure [7B](#F7){ref-type="fig"}**; *p* = 0.0195 for the Aba/Lam treated group; *p* = 0.0414 for the Lop/Rit treated group). These results suggest that the Aba/Lam and Lop/Rit combinations may inhibit lipid accumulation in differentiating adipocytes by down-regulating CEBPb adipogenic transcription factor expression.

Discussion
==========

This study was initiated based on our previous longitudinal, comprehensive, and population-based study performed in Taiwan, which demonstrated that cumulative ART use, ART adherence, and the type of regimen provided may increase hyperlipidemia risk in HIV-1-infected patients when compared to HIV-1-infected patients who did not receive ART treatment ([@B46]). A high risk of hyperlipidemia was observed in HIV-1-infected patients who received Aba/Lam, Lam/Zido, or Lop/Rit drug regimens. Therefore, in this study, we observed that daily oral administration of Aba/Lam or Lop/Rit for 4 weeks in mice can contribute to cognitive, motor, and metabolic impairment. Our results demonstrate that daily oral administration of Aba/Lam or Lop/Rit may produce cognitive, motor, and metabolic impairments in mice, regardless of HIV-1 infection.

Our results demonstrate that mice treated with either the Aba/Lam or Lop/Rit drug regimens exhibit cognitive impairment. Motor impairment was observed in mice treated with Aba/Lam, Lam/Zido, and Lop/Rit. These results suggest that in addition to HIV-1 infection, these ART drugs may also affect neurologic functions. Further, to investigate whether a correlation exists between HIV-1-infected patients receiving ART and neurological disorders, we performed a longitudinal and population-based study to investigate the effect of different ART regimens on the risk of neurological disorders in the Taiwanese HIV-1/ART cohort (**Supplementary Tables [S1](#SM2){ref-type="supplementary-material"}**, **[S2](#SM3){ref-type="supplementary-material"}**). We found that patients receiving nucleoside reverse-transcriptase inhibitors (NRTI/NRTI)-containing regimen had the risk of neurological disorders. Patients receiving PI-containing regimens had the risk of neurological disorders. HIV-1-associated neuropsychiatric disorders (HAND) are mainly due to HIV-1 infection and AIDS progression and remain a significant public health concern ([@B7]; [@B36]). HAND prevalence remains high even in the post-ART era ([@B19]; [@B10]; [@B6]). Although ART is known to protect the CNS against HIV-1 infection and prevent the development of local HIV-1 reservoirs, the effectiveness of CNS penetration by these ART drugs and their potential neurotoxicities need further study ([@B10]; [@B13]; [@B42]). Efavirenz is the ART drug that has been the most extensively studied in relation to HAND. Efavirenz has been associated with HAND in both human clinical studies and murine models ([@B40]; [@B44]; [@B26]) and has been shown to affect brain energy metabolism dysfunction, especially in the cerebral cortex, striatum, and hippocampus ([@B44]). In addition, Efavirenz promotes beta-secretase (BACE-1) expression and increases Aβ generation in SweAPP N2a neural cells and in a mouse model ([@B3]). However, Efavirenz lowered the clearance of Aβ peptide in primary microglial phagocytosis cells ([@B3]). Furthermore, Efavirenz reduced neural stem cell proliferation in rat NSC cells and in a mouse model ([@B22]). Lop/Rit led to poor performance in neurocognitive functioning in both HIV-1-infected patients ([@B26]) and mouse models ([@B37]; [@B17]). In addition, both Aba/Lam and Lop/Rit induced an increase in Aβ generation in SweAPP N2a neural cells and reduced the clearance of Aβ peptide in N9 microglial phagocytosis cells ([@B15]), suggesting that these ART drugs may contribute to the cognitive and motor decline observed in HIV-1-infected patients.

Our recent study demonstrated that factors including cumulative use, adherence, and the treatment regimen of ART given, may affect metabolic function, and particularly hyperlipidemia risk, in HIV-1-infected patients in a dose-dependent manner ([@B46]). HIV-1-infected patients receiving Aba/Lam-containing regimens were also found to have increased blood cholesterol levels ([@B32]). Lop/Rit has been also associated with hyperlipidemia in both human clinical studies and murine models ([@B17]; [@B48]; [@B28]). Our results also showed that treatment of mice with Aba/Lam and Lop/Rit enhanced the lipid accumulation in the liver, and decreased AMPK phosphorylation and/or the expression of ACC acetyl-CoA. ART drugs may bind to the LDL receptor-related protein (LRP), thereby inhibiting the function of the LRP-Lpl complex (the cleavage of fatty acids from plasma triglycerides) ([@B5]; [@B28]). ART drugs may also induce abnormal lipid metabolism by causing alterations in particular genes, including genes encoding sterol regulatory element-binding proteins, cytoplasmic retinoic-acid binding proteins, peroxisome proliferator activated receptors, and apoCIII ([@B38]; [@B28]). Furthermore, tissue lipids and hyperlipidemia may be affected by the signaling mechanism that is involved in phosphorylation and expression of AMPK protein and its downstream target, ACC protein, which is known to play a role in fatty acid oxidation and lipid synthesis ([@B50], [@B49]; [@B20]). The reduced signaling in AMPK and ACC proteins contributed to the impaired fatty acid oxidation and then resulted in lipid accumulation in liver tissue ([@B50], [@B49]; [@B20]). Our results also demonstrate that Aba/Lam, Lam/Zido, and Lop/Rit led to intracellular total cholesterol accumulation and decreased the phosphorylation of AMPK and ACC proteins *in vitro* HepG2 cells. Our results also showed that these ART drugs under AMPK antagonist dorsomorphin impaired the AMPK and ACC signaling pathway (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). The treatment of mice with AMPK antagonist dorsomorphin alone or combined with ART drugs will be investigated in our next study.

Our results demonstrate that Aba/Lam and Lop/Rit attenuate 3T3-L1 pre-adipocyte differentiation by inhibiting CEBPb adipogenic transcription factor expression, implicating the lipodystrophic syndrome. In addition, leptin serum levels were found to be reduced in mice treated with Aba/Lam. These results suggest that these ART drugs may affect body fat distribution and lipid metabolism ([@B31]; [@B43]). Indeed, long-term use of ART has been associated with lipodystrophic syndrome ([@B14]). Decreased levels of leptin have previously been observed in HIV-1-lipodystrophic patients ([@B45]; [@B47]). This decrease inversely correlates with the occurrence of hyperlipidemia ([@B34]). Leptin expression has been shown to be regulated by several transcriptional factors including CEBPb ([@B27]). Leptin therapy in HIV-1-lipodystrophic patients has been found to improve blood lipid profiles, and to decrease visceral fat without having any effect on subcutaneous or peripheral fat distribution ([@B33]; [@B47]). Furthermore, leptins are known to have a significant effect on the hippocampus, a key brain region for cognition, and therefore may play important roles in neurological complications ([@B29],[@B30]).

Several ART drugs are associated with HIV-1-associated lipodystrophy ([@B51]; [@B4]). Ritonavir has previously been associated with reduced triglyceride accumulation and was found to inhibit aP2, Lpl, and Adipoq adipogenic differentiation markers in 3T3-L1 pre-adipocyte differentiation ([@B51]). Zidovudine was found to reduce lipid content in differentiated 3T3-L1 pre-adipocytes by inhibiting FAS, ACC, and aP2 adipogenic markers ([@B4]). Lam/Zido and Aba/Lam/Zido also reduced lipid content in differentiated 3T3-L1 preadipocytes ([@B4]). Despite the beneficial effects on lipdystrophy observed in studies using thiazolidinediones ([@B12]), our results showed that PPARg was significantly reduced and thus may not be a druggable target. Our study demonstrates that Aba/Lam and Lop/Rit also reduce lipid accumulation in adipocytes by inhibiting CEBPb adipogenic transcription factor expression. Furthermore, serum leptin levels were found to be reduced in Aba/Lam-treated mice.

Conclusion
==========

In this study, there is a limitation of applicability of the mice cognitive function tests to human neurological disorders. The cognitive function tests used in mice are not absolutely relevant for the determining the neurological consequences in human. However, this study demonstrated that daily, oral administration of Aba/Lam and Lop/Rit may increase the likelihood of the development of cognitive, motor, and metabolic impairments in mice, regardless of HIV-1 infection. The AMPK-ACC signaling, CEBPb adipogenic transcription factor, and leptin may play roles in the molecular mechanisms of lipid metabolism and neuroprotection. Further studies are required to devise treatments that reduce or avoid the development of ART-associated metabolic and neurologic complications.
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###### 

Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) with dorsomorphin on lipid metabolism-related AMPK and ACC proteins in human HepG2 hepatocytes. **(A)** Effects of antiretroviral drugs (Aba/Lam, Lam/Zido, and Lop/Rit) with dorsomorphin on phosphorylation and expression of both AMPKa and ACC proteins by using Western blot analysis. **(B)** Relative ratios of band intensity of p-AMPKa/AMPKa and p-ACC/ACC when compared with the controls. All data are mean ± SEM for each group. Data are analyzed by the un-paired student *t*-test in the experimental groups Aba/Lam, Lam/Zido, or Lop/Rit-treated HepG2 cells as compared with the control cells. Dorsomorphin-treated HepG2 cells are used as the AMPK antagonist controls. Oleic acid-treated HepG2 cells are used as the controls to inhibit the AMPK and ACC signaling pathway.
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Click here for additional data file.

###### 

Demographic characteristics of HIV-1-infected patients with and without neurological disorders.
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Click here for additional data file.

###### 

Neurological disorder risk in HIV-1-infected patients according to single type of ART regimen.
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Click here for additional data file.
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